COLUMBIA, Md.--(BUSINESS WIRE)--Medifocus Inc. (OTC:MDFZF - News) and (TSXV:MFS) is pleased to announce, it has successfully initiated its first two clinical study sites to begin its Pivotal Phase III study for the treatment of large breast cancers.
The two clinical sites are at the University of Oklahoma Breast Institute in Oklahoma City and at the Comprehensive Breast Center of Coral Springs Florida, a division of 21st Century Oncology. The Pivotal Phase III clinical trial is designed to assess the safety and improvement in efficacy, as measured by increased tumor shrinkage, using the Company’s focused microwave heat energy in combination with neo-adjuvant (pre-operative) chemotherapy over chemotherapy alone on large breast cancer tumors.
Dr. Augustine Y. Cheung, President and CEO stated, “We are extremely pleased to have successfully initiated these two sites by providing training and installation of the Medifocus Breast Cancer Treatment system. We are looking forward for our sites to enroll our first breast cancer patient in our Pivotal Phase III study. This event will be a major milestone for Medifocus towards the commercialization of the treatment system.”
About Medifocus, Inc. :
Medifocus owns a patented adaptive phased array (APA) microwave focusing technology platform which can precisely target and concentrate microwave energy to destroy cancer tumors without damaging healthy tissue when used alone or in conjunction with chemotherapy or radiation. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness over those treatments alone, and to activate temperature sensitive drugs for tumor targeted localized drug delivery. Medifocus has completed the development of a dedicated commercial cancer treatment system for the treatment of breast cancer and is actively pursuing development of additional systems for other cancers.
Forward-Looking Statements and Information:
This news release contains forward-looking statements, which may not be based on historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.